论文部分内容阅读
目的观察女性乳腺癌中巯基二硫键氧化还原酶(ERP57)、抗原处理相关内质网氨肽酶(ERAP1)的表达情况,探讨其与乳腺癌各临床病理指标的关系。方法选取2011年1月—2015年12月于新疆医科大学附属肿瘤医院收集的124例乳腺癌肿瘤和24例乳腺纤维腺瘤组织标本,应用免疫组织化学SP法检测标本中ERP57及ERAP1的表达情况;根据临床病理参数对患者进行分组,分析各组之间ERP57、ERAP1的表达有无差异。结果ERP57在乳腺癌及乳腺纤维腺瘤中阳性表达率分别为58.8%(73/124)和100%(24/24),差异有统计学意义(χ~2=15.061,P<0.05);ERAP1阳性表达率分别为47.5%(59/124)和83.3%(20/24),差异有统计学意义(χ~2=10.328,P<0.05)。乳腺癌组织中ERP57、ERAP1阳性表达率比较,无腋窝淋巴结转移患者高于有腋窝淋巴结转移患者,组织学分级Ⅰ级患者高于Ⅱ~Ⅲ级患者,TNM分期Ⅰ~Ⅱ期患者高于Ⅲ~Ⅳ期患者,差异均有统计学意义(均P<0.05)。此外,乳腺癌组织中ERAP1阳性表达率比较,>35岁患者高于≤35岁患者。Ki67阳性率≤14%患者高于>14%患者,非三阴性患者高于三阴性患者,差异均有统计学意义(均P<0.05)。结论 ERP57、ERAP1蛋白低表达可能与乳腺癌的发生关系密切,这对判断乳腺癌恶性程度及预后有一定的参考价值。
Objective To investigate the expression of ERAP1 and ERK1 in female breast cancer and explore its relationship with the clinicopathological parameters of breast cancer. Methods 124 cases of breast cancer and 24 cases of breast fibroadenoma collected from the Affiliated Tumor Hospital of Xinjiang Medical University from January 2011 to December 2015 were selected. The expression of ERP57 and ERAP1 were detected by immunohistochemical SP method According to the clinicopathological parameters, the patients were divided into groups, and the differences of the expression of ERP57 and ERAP1 in each group were analyzed. Results The positive rate of ERP57 in breast cancer and breast fibroadenoma were 58.8% (73/124) and 100% (24/24) respectively, with statistical significance (χ ~ 2 = 15.061, P <0.05) The positive rates were 47.5% (59/124) and 83.3% (20/24) respectively, with statistical significance (χ ~ 2 = 10.328, P <0.05). The positive rates of ERP57 and ERAP1 in breast cancer tissues were higher than those in patients with axillary lymph node metastasis, the histological grade Ⅰ patients were higher than those in patients with grade Ⅱ ~ Ⅲ, the TNM stage Ⅰ ~ Ⅱ patients were higher than those in Ⅲ ~ Ⅳ patients, the differences were statistically significant (all P <0.05). In addition, ERAP1-positive expression rates in breast cancer were higher in patients> 35 years old than in patients ≤35 years. Ki67 positive rate of ≤ 14% of patients with> 14% of patients, non-triple negative patients were higher than triple negative patients, the difference was statistically significant (P <0.05). Conclusions The low expression of ERP57 and ERAP1 protein may be closely related to the occurrence of breast cancer, which is of certain reference value for judging the malignancy and prognosis of breast cancer.